Niraparib Therapy in Patients With Newly Diagnosed Advanced Ovarian …

Antonio González-Martín

2021 Updates on Gynecologic Oncology: Impact on Patients, Overview o…

University of Colorado Cancer Center

B. Bitler, S. Guntupalli, C. Walsh

Labeled Indications for PARPi Monotherapy & PARPi+ Bevacizumab: How …

Michael Birrer

PARPi in 1L Advanced Ovarian Cancer: PFS Data for Olaparib, Nirapari…

Angela George

Updates in Ovarian Cancer Management: Treatment Options and Molecula…

Total Health

M. Yatsko

Updates From the PRIMA Trial: Niraparib as 1L Maintenance in Advance…

Kenrick Ng

Targeting DNA Damage Response in Ovarian Cancer: Are PARPi Just the …

Nebraska Oncology Society

K. Moore

Targeted Therapy for Advanced Ovarian Cancer

Ramez Eskander

PARPi in DNA Repair-Associated Cancers: Predictors of Benefit, Mecha…

UChicago Genetics in Clinical Cancer Care: From Family Reunions to the Frontline of Developmental Therapeutics

G. Fleming

Developments in Frontline Therapy in Ovarian Cancer

Jonathan Ledermann

PARPi Maintenance Therapy in Advanced Ovarian Cancer: A Brief Review

Catherine Watson

SGO 2022: Recognition and Management of Side Effects Associated With…

SGO 2022 Conference Coverage on VuMedi

M. Raza Mirza

SGO 2022 on a Phase 2 OVARIO Study of Niraparib + Bevacizumab in Adv…

SGO 2022 Conference Coverage on VuMedi

M. Hardesty